Rupert W Strauss1,2,3,4, Xiangrong Kong1,5, Alexander Ho6, Anamika Jha6, Sheila West1, Michael Ip6, Paul S Bernstein7, David G Birch8, Artur V Cideciyan9, Michel Michaelides2, José-Alain Sahel10, Janet S Sunness11, Elias I Traboulsi12, Eberhart Zrenner13, Sean Pitetta6, Dennis Jenkins6, Amir Hossein Hariri6, SriniVas Sadda6, Hendrik P N Scholl1,14,15. 1. Wilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland. 2. Moorfields Eye Hospital National Health Services Foundation Trust and UCL Institute of Ophthalmology, University College London, London, United Kingdom. 3. Department of Ophthalmology, Johannes Kepler University Clinic Linz, Linz, Austria. 4. Department of Ophthalmology, Medical University Graz, Graz, Austria. 5. Department of Biostatistics and Epidemiology, University of Massachusetts, Amherst. 6. Doheny Eye Institute, David Geffen School of Medicine, University of California, Los Angeles. 7. Moran Eye Center, University of Utah School of Medicine, Salt Lake City. 8. Retina Foundation of the Southwest, Dallas, Texas. 9. Scheie Eye Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia. 10. Sorbonne Universités, University Pierre et Marie Curie Université de Paris 06, Institut National de la Santé et de la Recherche Médicale, Centre National de la Recherche Scientifique, Institut de la Vision, Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts, Paris, France. 11. Hoover Low Vision Rehabilitation Services, Greater Baltimore Medical Center, University of Maryland School of Medicine, Baltimore, Maryland. 12. Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio. 13. Center for Ophthalmology, Eberhard-Karls University Hospital, Tübingen, Germany. 14. Institute of Molecular and Clinical Ophthalmology Basel, Basel, Switzerland. 15. Department of Ophthalmology, University of Basel, Basel, Switzerland.
Abstract
IMPORTANCE: Sensitive outcome measures for disease progression are needed for treatment trials of Stargardt disease. OBJECTIVE: To estimate the progression rate of atrophic lesions in the prospective Natural History of the Progression of Atrophy Secondary to Stargardt Disease (ProgStar) study over a 12-month period. DESIGN, SETTING, AND PARTICIPANTS: This multicenter prospective cohort study was conducted in an international selection of tertiary referral centers from October 21, 2013, to February 15, 2017. Patients who were affected by Stargardt disease, aged 6 years and older at baseline, and harboring disease-causing variants of the ABCA4 gene were enrolled at 9 centers in the United States, United Kingdom, and continental Europe. Data analysis occurred from November 2016 to January 2017. EXPOSURES: Autofluorescence images obtained with a standard protocol were sent to a central reading center, and areas of definitely decreased autofluorescence, questionably decreased autofluorescence, and the total combined area of decreased autofluorescence were outlined and quantified. Progression rates were estimated from linear mixed models with time as the independent variable. MAIN OUTCOMES AND MEASURES: Yearly rate of progression, using the growth of atrophic lesions measured by autofluorescence imaging. RESULTS: A total of 259 study participants (488 eyes; 230 individuals [88.8%] were examined in both eyes) were enrolled (mean [SD] age at first visit, 33.3 [15.1] years; 118 [54.4%] female). Gradable images were available for evaluation for 480 eyes at baseline and 454 eyes after 12 months. At baseline, definitely decreased autofluorescence was present in 306 eyes, and the mean (SD) lesion size was 3.93 (4.37) mm2. The mean total area of decreased autofluorescence at baseline was 4.07 (4.04) mm2. The estimated progression of definitely decreased autofluorescence was 0.76 (95% CI, 0.54-0.97) mm2 per year (P < .001), and the total area of both questionably and definitely decreased autofluorescence was 0.64 (95% CI, 0.50-0.78) mm2 per year (P < .001). Both progression rates depended on initial lesion size. CONCLUSIONS AND RELEVANCE: In Stargardt disease, autofluorescence imaging may serve as a monitoring tool and definitely decreased autofluorescence and total area as outcome measures for interventional clinical trials that aim to slow disease progression. Rates of progression depended mainly on initial lesion size.
IMPORTANCE: Sensitive outcome measures for disease progression are needed for treatment trials of Stargardt disease. OBJECTIVE: To estimate the progression rate of atrophic lesions in the prospective Natural History of the Progression of Atrophy Secondary to Stargardt Disease (ProgStar) study over a 12-month period. DESIGN, SETTING, AND PARTICIPANTS: This multicenter prospective cohort study was conducted in an international selection of tertiary referral centers from October 21, 2013, to February 15, 2017. Patients who were affected by Stargardt disease, aged 6 years and older at baseline, and harboring disease-causing variants of the ABCA4 gene were enrolled at 9 centers in the United States, United Kingdom, and continental Europe. Data analysis occurred from November 2016 to January 2017. EXPOSURES: Autofluorescence images obtained with a standard protocol were sent to a central reading center, and areas of definitely decreased autofluorescence, questionably decreased autofluorescence, and the total combined area of decreased autofluorescence were outlined and quantified. Progression rates were estimated from linear mixed models with time as the independent variable. MAIN OUTCOMES AND MEASURES: Yearly rate of progression, using the growth of atrophic lesions measured by autofluorescence imaging. RESULTS: A total of 259 study participants (488 eyes; 230 individuals [88.8%] were examined in both eyes) were enrolled (mean [SD] age at first visit, 33.3 [15.1] years; 118 [54.4%] female). Gradable images were available for evaluation for 480 eyes at baseline and 454 eyes after 12 months. At baseline, definitely decreased autofluorescence was present in 306 eyes, and the mean (SD) lesion size was 3.93 (4.37) mm2. The mean total area of decreased autofluorescence at baseline was 4.07 (4.04) mm2. The estimated progression of definitely decreased autofluorescence was 0.76 (95% CI, 0.54-0.97) mm2 per year (P < .001), and the total area of both questionably and definitely decreased autofluorescence was 0.64 (95% CI, 0.50-0.78) mm2 per year (P < .001). Both progression rates depended on initial lesion size. CONCLUSIONS AND RELEVANCE: In Stargardt disease, autofluorescence imaging may serve as a monitoring tool and definitely decreased autofluorescence and total area as outcome measures for interventional clinical trials that aim to slow disease progression. Rates of progression depended mainly on initial lesion size.
Authors: Liangbo L Shen; Aneesha Ahluwalia; Mengyuan Sun; Benjamin K Young; Holly K Grossetta Nardini; Lucian V Del Priore Journal: Ophthalmol Retina Date: 2020-03-14
Authors: Etienne M Schönbach; Rupert W Strauss; Beatriz Muñoz; Yulia Wolfson; Mohamed A Ibrahim; David G Birch; Eberhart Zrenner; Janet S Sunness; Michael S Ip; SriniVas R Sadda; Sheila K West; Hendrik P N Scholl Journal: JAMA Ophthalmol Date: 2020-07-01 Impact factor: 7.389
Authors: Ruben Jauregui; Yan Nuzbrokh; Pei-Yin Su; Jana Zernant; Rando Allikmets; Stephen H Tsang; Janet R Sparrow Journal: Transl Vis Sci Technol Date: 2021-01-05 Impact factor: 3.283
Authors: Todd A Durham; Jacque L Duncan; Allison R Ayala; David G Birch; Janet K Cheetham; Frederick L Ferris; Carel B Hoyng; Mark E Pennesi; José-Alain Sahel Journal: Transl Vis Sci Technol Date: 2021-04-01 Impact factor: 3.048
Authors: Alexandra V Garafalo; Artur V Cideciyan; Elise Héon; Rebecca Sheplock; Alexander Pearson; Caberry WeiYang Yu; Alexander Sumaroka; Gustavo D Aguirre; Samuel G Jacobson Journal: Prog Retin Eye Res Date: 2019-12-30 Impact factor: 21.198
Authors: Debra A Thompson; Alessandro Iannaccone; Robin R Ali; Vadim Y Arshavsky; Isabelle Audo; James W B Bainbridge; Cagri G Besirli; David G Birch; Kari E Branham; Artur V Cideciyan; Steven P Daiger; Deniz Dalkara; Jacque L Duncan; Abigail T Fahim; John G Flannery; Roberto Gattegna; John R Heckenlively; Elise Heon; K Thiran Jayasundera; Naheed W Khan; Henry Klassen; Bart P Leroy; Robert S Molday; David C Musch; Mark E Pennesi; Simon M Petersen-Jones; Eric A Pierce; Rajesh C Rao; Thomas A Reh; Jose A Sahel; Dror Sharon; Paul A Sieving; Enrica Strettoi; Paul Yang; David N Zacks Journal: Transl Vis Sci Technol Date: 2020-06-03 Impact factor: 3.283
Authors: Maria Vittoria Cicinelli; Alessandro Rabiolo; Maria Brambati; Chiara Viganò; Francesco Bandello; Maurizio Battaglia Parodi Journal: Transl Vis Sci Technol Date: 2020-06-25 Impact factor: 3.283
Authors: S Scott Whitmore; Christopher R Fortenbach; Justine L Cheng; Adam P DeLuca; D Brice Critser; Elizabeth L Geary; Jeremy M Hoffmann; Edwin M Stone; Ian C Han Journal: Sci Rep Date: 2020-10-06 Impact factor: 4.379